Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse".

MLA

Karpov, Dmitry S., et al. “Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a ‘Trojan Horse.’” International Journal of Molecular Sciences, vol. 24, no. 24, Dec. 2023. EBSCOhost, https://doi.org/10.3390/ijms242417320.

APA

Karpov, D. S., Sosnovtseva, A. O., Pylina, S. V., Bastrich, A. N., Petrova, D. A., Kovalev, M. A., Shuvalova, A. I., Eremkina, A. K., & Mokrysheva, N. G. (2023). Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse.” International Journal of Molecular Sciences, 24(24). https://doi.org/10.3390/ijms242417320

Chicago

Karpov, Dmitry S, Anastasiia O Sosnovtseva, Svetlana V Pylina, Asya N Bastrich, Darya A Petrova, Maxim A Kovalev, Anastasija I Shuvalova, Anna K Eremkina, and Natalia G Mokrysheva. 2023. “Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a ‘Trojan Horse.’” International Journal of Molecular Sciences 24 (24). doi:10.3390/ijms242417320.